Follow
Ghulam Mufti
Ghulam Mufti
Professor of Haemato-Oncology, King's College
Verified email at kcl.ac.uk
Title
Cited by
Cited by
Year
International scoring system for evaluating prognosis in myelodysplastic syndromes
P Greenberg, C Cox, MM LeBeau, P Fenaux, P Morel, G Sanz, M Sanz, ...
Blood, The Journal of the American Society of Hematology 89 (6), 2079-2088, 1997
56081997
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, ...
The lancet oncology 10 (3), 223-232, 2009
30462009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, ...
Journal of clinical oncology 28 (4), 562-569, 2010
11782010
‘Off-the-shelf’allogeneic CAR T cells: development and challenges
S Depil, P Duchateau, SA Grupp, G Mufti, L Poirot
Nature reviews Drug discovery 19 (3), 185-199, 2020
9272020
Guidelines for the diagnosis and management of adult aplastic anaemia.
SB Killick, N Bown, J Cavenagh, I Dokal, T Foukaneli, A Hill, P Hillmen, ...
British journal of haematology 172 (2), 2016
8202016
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
L Malcovati, E Hellström-Lindberg, D Bowen, L Adès, J Cermak, ...
Blood, The Journal of the American Society of Hematology 122 (17), 2943-2964, 2013
8172013
Myelodysplastic syndromes: a scoring system with prognostic significance
GJ Mufti, JR Stevens, DG Oscier, TJ Hamblin, D Machin
British journal of haematology 59 (3), 425-433, 1985
6691985
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
M Jädersten, L Saft, A Smith, A Kulasekararaj, S Pomplun, G Göhring, ...
Journal of clinical oncology 29 (15), 1971-1979, 2011
5792011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
P Fenaux, A Giagounidis, D Selleslag, O Beyne-Rauzy, G Mufti, ...
Blood, The Journal of the American Society of Hematology 118 (14), 3765-3776, 2011
5752011
Luspatercept in patients with lower-risk myelodysplastic syndromes
P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ...
New England Journal of Medicine 382 (2), 140-151, 2020
5032020
The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS
JE Parker, GJ Mufti, F Rasool, A Mijovic, S Devereux, A Pagliuca
Blood, The Journal of the American Society of Hematology 96 (12), 3932-3938, 2000
4842000
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical …
R Martino, S Iacobelli, R Brand, T Jansen, A van Biezen, J Finke, ...
Blood 108 (3), 836-846, 2006
4372006
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.
D Bowen, D Culligan, S Jowitt, S Kelsey, G Mufti, D Oscier, J Parker
British journal of haematology 120 (2), 2003
4342003
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the …
GJ Mufti, JM Bennett, J Goasguen, BJ Bain, I Baumann, R Brunning, ...
haematologica 93 (11), 1712-1717, 2008
4212008
Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin
JW Janssen, M Buschle, M Layton, HG Drexler, J Lyons, ...
4051989
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
T De Witte, D Bowen, M Robin, L Malcovati, D Niederwieser, ...
Blood, The Journal of the American Society of Hematology 129 (13), 1753-1762, 2017
3922017
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia
ZY Lim, R Brand, R Martino, A van Biezen, J Finke, A Bacigalupo, ...
Journal of Clinical Oncology 28 (3), 405-411, 2010
3632010
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells
A Essafi, S Fernández de Mattos, YAM Hassen, I Soeiro, GJ Mufti, ...
Oncogene 24 (14), 2317-2329, 2005
3522005
Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia …
J Donadieu, T Leblanc, BB Meunier, M Barkaoui, O Fenneteau, ...
haematologica 90 (1), 45-53, 2005
3502005
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd–Chiari syndrome
RK Patel, NC Lea, MA Heneghan, NB Westwood, D Milojkovic, ...
Gastroenterology 130 (7), 2031-2038, 2006
3412006
The system can't perform the operation now. Try again later.
Articles 1–20